- Home
- SQFT vs MYNZ Comparison
SQFT vs MYNZ Comparison
Compare SQFT & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- MYNZ
- Stock Information
- Founded
- SQFT 1999
- MYNZ 2021
- Country
- SQFT United States
- MYNZ Germany
- Employees
- SQFT N/A
- MYNZ N/A
- Industry
- SQFT Real Estate Investment Trusts
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- MYNZ Health Care
- Exchange
- SQFT Nasdaq
- MYNZ Nasdaq
- Market Cap
- SQFT 7.7M
- MYNZ 7.9M
- IPO Year
- SQFT 2020
- MYNZ 2021
- Fundamental
- Price
- SQFT $4.88
- MYNZ $1.61
- Analyst Decision
- SQFT
- MYNZ Buy
- Analyst Count
- SQFT 0
- MYNZ 2
- Target Price
- SQFT N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- SQFT 22.1K
- MYNZ 107.2K
- Earning Date
- SQFT 08-14-2025
- MYNZ 10-21-2025
- Dividend Yield
- SQFT N/A
- MYNZ N/A
- EPS Growth
- SQFT N/A
- MYNZ N/A
- EPS
- SQFT N/A
- MYNZ N/A
- Revenue
- SQFT $18,052,597.00
- MYNZ $893,991.00
- Revenue This Year
- SQFT $23.63
- MYNZ $26.06
- Revenue Next Year
- SQFT N/A
- MYNZ $4.97
- P/E Ratio
- SQFT N/A
- MYNZ N/A
- Revenue Growth
- SQFT N/A
- MYNZ N/A
- 52 Week Low
- SQFT $4.19
- MYNZ $1.30
- 52 Week High
- SQFT $23.00
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- SQFT 41.47
- MYNZ 44.61
- Support Level
- SQFT $4.76
- MYNZ $1.70
- Resistance Level
- SQFT $5.03
- MYNZ $1.79
- Average True Range (ATR)
- SQFT 0.31
- MYNZ 0.11
- MACD
- SQFT 0.01
- MYNZ -0.00
- Stochastic Oscillator
- SQFT 34.21
- MYNZ 3.33
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.